Date: 2011-04-28
Type of information: Initiation of preclinical development
phase: 2-3
Announcement:
Company: Mologen (Germany)
Product: MGN1703 (lefitolimod)
Action
mechanism: immunotherapy product/TLR9 agonist. Lefitolimod (MGN1703) is based on dSLIM® (“double Stem Loop Immunomodulator”), a DNA-based TLR9 agonist developed by Mologen. dSLIM® activates the immune system against tumor-associated antigens by targeting various receptors on certain immune cells, primarily TLR9. Tumor-associated antigens (TAA) are released by cancer cells as a result of chemotherapy and radiation therapy. Once activated by dSLIM®, the immune system is able to overcome its fatal tolerance toward cancer cells and TAA and attacks them selectively. Treatment with lefitolimod (MGN1703) triggers a broad and strong activation of the immune system. Due to this mechanism of action, lefitolimod (MGN1703) has the potential to be applied to various indications.
Disease: colorectal cancer
Therapeutic area: Cancer - Oncology
Country: Russia
Trial details:
Latest
news: Mologen has anounced that the company is now starting the implementation of a clinical trial II/III with the colorectal cancer medicine MGN1703 in Russia. The clinical trial is to be carried out in study centers in the Greater Moscow area and other Russian cities. The company has announced that it had been waiting with some tension for commencement of the trial in Russia, since the approval process took place at the same time as the extensive amendment to the Russian drug law and changes in official responsibilities. This led to a delay in the start of the study there.
Commencement of the intermediate evaluation expected in the 2nd half of 2011 and Mologen currently expects to be able to commence the intermediate evaluation of the international clinical trial II/III with MGN1703 in the 2nd half of this year.
